Santarus, Inc., a specialty biopharmaceutical company, focuses on acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company offers UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis; and ZEGERID (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders. It also provides GLUMETZA (metformin hydrochloride extended release tablets) and CYCLOSET (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; ...
3611 Valley Centre Drive
San Diego, CA 92130
Founded in 1996
Santarus, Inc. Announces Consolidated Audited Earnings Results for the Year Ended Dec. 31, 2013
May 30 14
Santarus, Inc. announced consolidated audited earnings results for the year ended Dec. 31, 2013. For the year, the company reported net product revenues of $933,838,000, income from operations of $271,713,000, income before provision for income tax of $212,065,000, net income of $143,034,000 or $2.18 per diluted share, net cash provided by operating activities of $415,855,000, purchases of property and equipment of $6,936,000 compared to the net product revenues of $735,444,000, income from operations of $172,073,000, income before provision for income tax of $111,828,000, net income of $64,246,000 or $1.01 per diluted share, net cash provided by operating activities of $87,592,000, purchases of property and equipment of $5,370,000 for the previous year.
Santarus, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-27-2014 08:30 AM
Feb 23 14
Santarus, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-27-2014 08:30 AM. Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Michael D. Step, Senior Vice President of Corporate Development.
Plaintiff Announces Securities Class Action against Santarus
Jan 31 14
Plaintiffs alleged that Santarus Inc. violated federal securities laws by making material misstatements and/or omissions in materials and statements disseminated in connection with the company's proposed merger with Salix Pharmaceuticals Inc. The plaintiffs specifically allege that Santarus fraudulently failed to disclose key information regarding the proposed merger, including: the process by which the Santarus board of directors came to agree on the proposed transaction: the analysis by the Santarus board's financial advisor on the fairness of the proposed transaction and the process by which the Santarus board decided to proceed with the merger with Salix rather than shopping for competing offers. Class period: July 11, 2013.